4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

Status Completed

Clinical Trial Summary

This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine whether a PET/CT scoring system in invasive biopsy proven anal squamous cell carcinoma (SCCA) to be treated with chemoradiation with curative intent (any T any N) predicts for overall survival (OS). SECONDARY OBJECTIVES: I. To determine whether a PET/CT scoring system in invasive biopsy proven SCCA to be treated with definitive chemoradiation with curative intent predicts for progression free survival (PFS). II. To determine and validate inter-reader reliability. III. To calculate C-index to evaluate the prognostic capacity of PET/CT scores for survival. IV. To determine the association between pre-treatment PET/CT scores after treatment and OS. EXPLORATORY OBJECTIVE: I. To correlate level of standardized uptake value (SUV) pre and post therapy and its correlation with overall survival. OUTLINE: Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients' medical records are received. Patients are followed up for 5 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05130073
Study type	Observational
Source	M.D. Anderson Cancer Center
Contact
Status	Completed
Phase
Start date	July 31, 2019
Completion date	December 14, 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05060471` - PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients	Phase 2
Recruiting	`NCT06050707` - MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach	Phase 2
Completed	`NCT04616196` - Study of NKTR 255 in Combination With Cetuximab in Solid Tumors	Phase 1/Phase 2
Completed	`NCT01285778` - Vectibix for the Treatment of Anal Cancer	Phase 2
Terminated	`NCT04596033` - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy	Phase 1
Recruiting	`NCT05374252` - Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients	Phase 3
Recruiting	`NCT05838391` - Adaptive Radiation in Anal Cancer	N/A
Completed	`NCT01807546` - Oral Rigosertib for Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05328765` - A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
Recruiting	`NCT05438836` - Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Terminated	`NCT02407561` - Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays	N/A
Completed	`NCT01115790` - A Phase 1 Study in Participants With Advanced Cancer	Phase 1
Recruiting	`NCT04929028` - Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer	Phase 2
Active, not recruiting	`NCT02560298` - Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer	Phase 2
Withdrawn	`NCT05582031` - Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers	Phase 2
Active, not recruiting	`NCT02437851` - Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection	Phase 2